CorMedix/$CRMD
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About CorMedix
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.
Ticker
$CRMD
Sector
Primary listing
Employees
65
Headquarters
Website
CorMedix Metrics
BasicAdvanced
$866M
14.01
$0.79
1.71
-
Price and volume
Market cap
$866M
Beta
1.71
52-week high
$17.43
52-week low
$5.60
Average daily volume
3.9M
Financial strength
Current ratio
7.822
Quick ratio
7.367
Long term debt to equity
0.117
Total debt to equity
0.197
Interest coverage (TTM)
1,344.06%
Profitability
EBITDA (TTM)
49.875
Gross margin (TTM)
95.62%
Net profit margin (TTM)
42.11%
Operating margin (TTM)
40.60%
Effective tax rate (TTM)
1.01%
Revenue per employee (TTM)
$1,870,000
Management effectiveness
Return on assets (TTM)
19.86%
Return on equity (TTM)
38.35%
Valuation
Price to earnings (TTM)
14.012
Price to revenue (TTM)
5.786
Price to book
3.75
Price to tangible book (TTM)
3.78
Price to free cash flow (TTM)
23.116
Free cash flow yield (TTM)
4.33%
Free cash flow per share (TTM)
0.48
Growth
Revenue change (TTM)
14,970.29%
Earnings per share change (TTM)
-185.14%
3-year revenue growth (CAGR)
894.87%
10-year revenue growth (CAGR)
82.99%
3-year earnings per share growth (CAGR)
-0.52%
10-year earnings per share growth (CAGR)
-13.55%
What the Analysts think about CorMedix
Analyst ratings (Buy, Hold, Sell) for CorMedix stock.
Bulls say / Bears say
CorMedix reported preliminary Q1 2025 net revenue of $39.0 million and expects adjusted EBITDA above $22.5 million, reflecting accelerating uptake of DefenCath in its early commercial phase (CorMedix)
A Large Dialysis Organization customer has increased DefenCath usage by at least 50%, prompting management to raise H1 2025 net sales guidance from $31 million to $35–40 million, underscoring robust demand (Investing.com)
Shares surged 21.7% to a four-year high after the expanded LDO agreement, signaling strong investor confidence in DefenCath’s market potential and validating CorMedix’s commercialization strategy (Investor's Business Daily)
The Medicare Transitional Drug Add-on Payment Adjustment will shift to a volume-based model later this year, making sustained high utilization of DefenCath critical and potentially pressuring reimbursement rates and margins (Investor's Business Daily)
CorMedix’s revenue remains entirely dependent on its single marketed product, DefenCath, while its broader pipeline is limited to early-stage clinical studies, heightening execution and regulatory risks if adoption slows or trials falter (CorMedix)
Future growth hinges on finalizing a deal with DaVita, which covers roughly 40% of U.S. outpatient dialysis centers; delays or unfavorable terms could significantly impede market penetration (Investor's Business Daily)
Data summarised monthly by Lightyear AI. Last updated on 8 Oct 2025.
CorMedix Financial Performance
Revenues and expenses
CorMedix Earnings Performance
Company profitability
CorMedix News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for CorMedix stock?
CorMedix (CRMD) has a market cap of $866M as of October 09, 2025.
What is the P/E ratio for CorMedix stock?
The price to earnings (P/E) ratio for CorMedix (CRMD) stock is 14.01 as of October 09, 2025.
Does CorMedix stock pay dividends?
No, CorMedix (CRMD) stock does not pay dividends to its shareholders as of October 09, 2025.
When is the next CorMedix dividend payment date?
CorMedix (CRMD) stock does not pay dividends to its shareholders.
What is the beta indicator for CorMedix?
CorMedix (CRMD) has a beta rating of 1.71. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.